A prostate cancer diagnosis is rarely an emergency. Most prostate cancers are caught early, grow slowly, and have excellent outcomes. About 69% of cases are diagnosed while still confined to the prostate, and the five-year survival rate for localized disease is effectively 100%. Even cancer that has spread to nearby lymph nodes carries a five-year survival rate of 100%. That context matters because the weeks after diagnosis can feel overwhelming, and knowing the odds are strongly in your favor can help you make clear-headed decisions about what comes next.
Here’s what the process typically looks like, from understanding your pathology report through treatment and recovery.
Understanding Your Pathology Report
Within days of your biopsy, you’ll receive a pathology report that contains two critical pieces of information: your Gleason score and your cancer’s stage. These numbers drive every decision that follows.
The Gleason score describes how aggressive your cancer cells look under a microscope. A pathologist assigns two numbers (each from 1 to 5) based on the two most common cell patterns in your biopsy samples, then adds them together. A Gleason 3+3=6 means the cells still form recognizable gland structures and tend to grow slowly. A 3+4=7 is mostly well-formed with some poorly formed areas. A 4+3=7 flips that ratio, with more abnormal tissue. Scores of 8, 9, or 10 indicate increasingly aggressive disease.
These scores are now organized into five Grade Groups that are easier to interpret. Grade Group 1 (Gleason 6) is the lowest risk. Grade Group 2 (Gleason 3+4) and Grade Group 3 (Gleason 4+3) represent intermediate risk, though Group 3 is more concerning. Grade Groups 4 and 5 (Gleason 8 through 10) are high risk. Your doctor will combine your Grade Group with your PSA level and clinical stage to classify your cancer as low, intermediate, or high risk overall.
How Staging Works
Staging tells you where the cancer is and whether it has spread. The system uses T, N, and M categories. The T stage describes the tumor itself. T1 means the cancer is too small to feel during a rectal exam or see on imaging; it was found through a biopsy triggered by elevated PSA or discovered incidentally during surgery for an enlarged prostate. T2 means the tumor can be felt during an exam but appears confined to the prostate. T3 means the cancer has grown beyond the prostate wall, and T4 means it has reached nearby structures like the bladder or rectum.
N indicates whether cancer has reached nearby lymph nodes. M1 means it has spread to distant sites: distant lymph nodes (M1a), bones (M1b), or organs like the liver or lungs (M1c). Only about 8% of prostate cancers are diagnosed at the distant stage.
For intermediate and high-risk cancers, your doctor may order advanced imaging. A PSMA PET scan is now considered superior to traditional CT and bone scans for detecting spread to lymph nodes or distant sites. It’s increasingly used for staging in men with Grade Group 3 or higher disease.
Active Surveillance for Low-Risk Cancer
If your cancer is Grade Group 1 (Gleason 6), your doctor will likely recommend active surveillance rather than immediate treatment. This isn’t ignoring the cancer. It’s a structured monitoring program that avoids the side effects of surgery or radiation for a cancer that may never cause harm.
A typical active surveillance schedule looks like this: a confirmatory biopsy within 6 to 24 months of diagnosis to make sure the initial findings are accurate, PSA blood tests every three to six months, a digital rectal exam once a year, and repeat biopsies every one to five years depending on how your numbers trend. If monitoring reveals the cancer is becoming more aggressive, you move to treatment at that point, with outcomes that remain excellent.
Many men stay on active surveillance for years or even indefinitely. It’s the recommended approach at major cancer centers for low-risk disease, not a compromise.
Surgery: What Recovery Looks Like
For cancers that need treatment, radical prostatectomy (removal of the prostate) is one of the most common options. Most procedures today are done robotically, which means smaller incisions, less blood loss, and faster recovery compared to open surgery.
You’ll typically go home one to two days after the operation. A urinary catheter stays in place for 7 to 14 days. During that time you won’t be able to drive. You’ll need to avoid bending, pulling, pushing, and heavy lifting for at least four weeks, and most people return to their normal routine within four to six weeks.
The two side effects that concern men most are urinary leakage and erectile dysfunction. Continence recovery is gradual. About 30% of men need no pads at three months after robotic surgery. That number rises to roughly 58% at six months and 79% at one year. Pelvic floor exercises (Kegels), often started before surgery, can speed this timeline. Erectile function recovery depends heavily on whether the surgeon can spare the nerves that run alongside the prostate, which in turn depends on the cancer’s location and extent.
Radiation: Fewer Sessions Than You Might Think
External beam radiation is the main alternative to surgery for localized prostate cancer. The traditional approach, called intensity-modulated radiation therapy, involves around 42 treatment sessions delivered over eight to nine weeks, typically as brief daily appointments on weekdays.
A newer option, stereotactic body radiation therapy, delivers higher doses per session and completes the entire course in as few as five visits. Both approaches have similar effectiveness for many patients, though they carry slightly different side effect profiles. Your radiation oncologist can help determine which is appropriate based on your cancer’s characteristics.
Radiation side effects tend to develop gradually during and after treatment. Bowel irritation, urinary frequency, and fatigue are common during the treatment course and usually improve over weeks to months afterward. Erectile dysfunction is a longer-term concern: among men with normal function before radiation, about 36% develop ED within the first year, and that number rises to roughly 59% by two years.
Hormone Therapy and Its Effects
Androgen deprivation therapy, which lowers testosterone levels, is used in several scenarios: alongside radiation for intermediate or high-risk cancer, as treatment for cancer that has spread, or when cancer returns after initial treatment. Because testosterone affects far more than the prostate, the side effects can be wide-ranging.
Common effects include hot flashes, loss of interest in sex, erectile dysfunction, fatigue, weight gain, and mood changes. Over time, reduced testosterone also leads to loss of bone density and muscle mass, changes in cholesterol levels, and increased insulin resistance. These metabolic shifts raise the risk of fractures and cardiovascular problems during long-term use.
Men on extended hormone therapy are often prescribed bone-protective medications to counteract bone loss. Regular weight-bearing exercise and resistance training can help preserve muscle mass, bone strength, and metabolic health. These aren’t optional extras; they’re an important part of managing life on hormone therapy.
Survival Rates by Stage
The numbers for prostate cancer are more favorable than for nearly any other cancer. Based on data from 2015 to 2021, the five-year relative survival rate is 100% for localized cancer (confined to the prostate) and 100% for regional cancer (spread to nearby lymph nodes). Together, these categories account for 83% of all diagnoses. For distant-stage cancer that has spread to bones or organs, the five-year survival rate is 37.9%.
“Relative survival” means these figures compare prostate cancer patients to men of the same age in the general population. A rate of 100% doesn’t mean no one dies; it means the cancer itself isn’t reducing life expectancy beyond what would be expected without it.
Practical Steps After Diagnosis
The period between diagnosis and starting treatment (or surveillance) is usually several weeks, and that window exists for good reason. Prostate cancer rarely requires urgent action, and using that time well leads to better decisions.
Consider getting a second opinion, particularly from a major cancer center if your initial diagnosis came from a community hospital. Ask whether genomic testing of your biopsy tissue could help clarify your risk level. These tests analyze the activity of specific genes in your tumor and can sometimes reclassify a cancer that looks intermediate-risk on biopsy into a lower or higher category, which changes the treatment conversation.
If you’re weighing surgery versus radiation, ask each specialist about their institution’s outcomes for your specific risk category. Outcomes vary by provider volume and expertise. Ask about expected side effects specific to your situation, not just general statistics, since factors like your age, anatomy, baseline urinary and sexual function, and the cancer’s location within the prostate all influence what you’ll experience afterward.